Factors Determining Primary Coronary Slow Flow Phenomenon among Opium Users and Non-users: A Case Control Study in Northern Iran

Hamid Reza Javadi†, Seyed Mostafa Mirakbari‡*, Abbas Allami‡, Ebrahim Salavati†

1Department of Cardiology, Bu Ali Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
2Department of Clinical Toxicology, Bu Ali Hospital, Qazvin University of Medical Sciences, Qazvin, Iran
3Department of Infectious Diseases, Bu Ali Hospital, Qazvin University of Medical Sciences, Qazvin, Iran

Abstract
Background: Coronary slow flow phenomenon (CSFP) represents a clinical entity with recurrent chest pain leading to living impairment. The present study aimed to investigate whether opium use correlates with primary CSFP.
Methods: This study included Iranian patients with suspected coronary artery disease who underwent myocardial perfusion imaging. Coronary blood flow was measured quantitatively using the thrombolysis in myocardial infarction (TIMI) frame count and slow flow was defined as TIMI grade 2 standard deviations. Age and clinical conditions including diabetes mellitus (DM), hypertension (HTN), hyperlipidemia (HLP), history of chest pain, and opium use were recorded. First, the characteristics of the two groups were compared and then the main analyses were conducted to examine the relationship between CSFP and opium use. Data were analyzed using t test and chi-square test via SPSS 25.0. The significance level was set at P<0.05.
Findings: This study was conducted on 44 male patients with documented CSFP who had no stenotic lesions and 134 control group male patients who had normal coronary arteries with normal flow. The mean age was similar in the two groups (54.25 vs.52.69, P=0.474). Two groups were significantly different in terms of history of chest pain (P=0.003), but there was no significant difference in HTN (P=0.084), DM (P=0.284), HLP (P=0.183), smoking (P=0.696), and opium use (P=0.107).
Conclusion: This study indicated that opium use is not associated with primary CSFP.
Keywords: Angiography, Chest pain, Coronary artery disease, Opium, Slow flow phenomenon

Introduction
Opium and opiates have been used for centuries as sedative and pain relief drugs.1 In addition, they have had great influence on human mood and behavior and have resulted in widespread abuse and addiction despite the awareness about their adverse effects on health.1,2 Opium has been the first narcotic choice among Iranians for medicinal and recreational purposes.4 Opium addiction is more common in Middle Eastern countries particularly Afghanistan, Pakistan, and Iran.5 Qazvin is among the first six provinces of Iran in terms of high prevalence of drug addict arrests following Gilan and Hormozgan provinces. Decrease in the age of addicts (from 25 years in 2011 to 15 years in 2015), increase in drug use among women (from 5% in 2011 to 10% in 2015), increase in drug use among educated people, and increase in synthetic addictive drugs have been observed.6

There are traditional positive beliefs about opium particularly in the elderly and patients suffering from chronic illness such as cardiovascular diseases.7,8 As deduced from some old resources, there is a popular assumption that opium acts as a complementary treatment for coronary diseases, hypertension (HTN), and diabetes mellitus (DM).9 Coronary slow flow phenomenon (CSFP) is an underrecognized risk factor for patients with chest pain and abnormal noninvasive ischemia with non-obstructive coronary arteries.10 The CSFP is an important angiographic entity characterized by delayed progression of the injected contrast medium through the coronary tree. It is a frequently encountered finding, typically observed in patients with acute coronary syndromes. Although it is well known to cardiologists over many decades of time, the mechanisms resulting in this phenomenon are still unclear.11

Although many previous studies available in the literature on Iranians have questioned the beneficial and protective properties of opium in cardiovascular risk factors,12,13 little has been documented about the correlation of opium use with CSFP. Therefore, this study aimed to investigate whether opium use correlates with

*Corresponding Author: Seyed Mostafa Mirakbari, MD, Email: dmirakbari@yahoo.com
primary CSFP.

Methods

Study design and data sources

This cross-sectional case control study was conducted at the cardiology department of Bu Ali hospital, an inner-city tertiary care hospital affiliated to Qazvin University of Medical sciences (QUMS), from August 2016 to August 2017. All patients admitted to the hospital with chest pain underwent thorough medical examination and cardiac tests. Predefined exclusion criteria were implemented to enroll study participants (Figure 1). The participants were informed of the purpose of the study and the interviews were conducted by a cardiology resident. Each participant signed an informed consent and self-reported opium use. The study protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by the institution’s human research committee. This study was approved by the institutional review board and strictly followed the institution’s ethical guidelines.

Clinical data

Previous medical history of patients was obtained and all clinical entities that could mimic or contribute to the CSFP and the secondary CSFP were excluded. To minimize diagnostic bias, some clinical conditions were defined with identical interpretation standards including myocardial infarction with elevated troponin I level and serial electrocardiogram, chronic kidney disease with glomerular filtration rate (GFR) < 60 mL/min/1.73 m², chronic obstructive pulmonary disease with abnormal spirometry, and anemia with hemoglobin concentration less than 13 mg/dL in adult males. For all troponin tests,
the cut-off values recommended by the manufacturers of tests were considered in their own population of patients. The blood samples for cardiac troponin I (cTnI) concentrations were measured using ARCH STAT Troponin-I, Abbott Diagnostics (cut-off value: 0.009 ng/mL, 99th percentile: 0.012, 10% coefficient of variation: 0.032, ROC curve: 0.3). An internist was consulted when needed. History of chest pain was defined as prior experience of clinical presentations consistent with myocardial ischemia in patients without significant coronary occlusion in angiography.

Definition of exposures and outcomes
A quantitative index of coronary flow, corrected thrombolysis in myocardial infarction (TIMI) frame count (CTFC), that represents the number of cine-frames required for contrast to first reach standardized distal coronary landmarks was implemented for flow assessment, and slow flow was defined as TIMI grade 2 standard deviations (SD) from normal published range.14-16 Figure 1 illustrates the research design and various stages of including and excluding the cases. In accordance with the predefined exclusion criteria, all patients in the primary slow flow group were male. Thus, the control group included randomly selected males with coronary normal flow (CNF) and females were excluded to reduce the confounding bias in adjustment analysis. Frequency of opium users in case group was compared with that of the control group. Opium users were included in the study if they were opium-dependent and smoked or orally consumed opium regularly at least 5 days a week for at least one year and were labeled as opium users. Those who had quitted opium consumption were classified as former users (past history of opium use), hence excluded from the study.

Statistical analysis
Data were analyzed using the Statistical Package for Social Sciences (IBM SPSS) version 25. Descriptive statistical analysis was used to calculate absolute frequency and percentage for qualitative data and mean ± standard deviation (SD) for quantitative data. T-test was used to compare continuous variables in case of normal distribution of variance and nonparametric tests were used in case of non-normal distribution of variables. Chi-square test and Fisher exact test were used to determine the frequency distribution in the agreement tables. Pearson’s and spearman’s correlation tests were utilized to determine unadjusted bivariate correlation between two variables. The P value less than 0.05 was considered significant.

Results
Patient characteristics
A total of 4845 cases underwent angiography during the study period. After excluding the cases based on the predefined exclusion criteria and randomly selecting CNF to match case group, 178 male cases were enrolled in the study. A total of 44 cases with primary slow flow phenomenon were assigned to the case group and 134 cases with normal coronary flow were allocated to the control group. The mean age of patients with CSFP was 54 ± 13 years (range 35 to 81 years). The most prevalent risk factor for coronary disease in CSFP patients was HTN (43.2%). Two study groups were further compared with respect to the defined demographic and clinical characteristics (Table 1).

Primary outcome analysis
According to chi-square analysis, there was no significant difference between CNF and CSFP groups regarding opium use (P = 0.107). Moreover, there were no significant differences between these groups regarding age (P = 0.474), cigarette smoking (P = 0.696), ejection fraction (P = 0.207), DM (P = 0.284), HTN (P = 0.084), and HLP (P = 0.183). History of chest pain was significantly higher in case group in comparison with the control group (P = 0.003) (Table 1).

The results of univariate analysis showed that the number of slow flow vessels in angiography was closely related to chest pain history (r = 0.250, p = 0.001), but not to other variables (Table 2).

Discussion
Findings/meaning
There are limited specific data on predisposing factors for CSFP in the medical literature. The results of this study indicated that opium use is not associated with higher CSFP in adult males. Previous studies on different ethnic groups have found different risk factors to be associated with CSFP.15

Comparison with related studies
In a study on Australian participants, the male sex and smoking were found to be independent risk factors,17 while a study on Chinese participants reported DM as an independent risk factor associated with CSFP.18 Two studies in Iran, both conducted in Kerman province addressed the correlation of opium use with CSFP.19,20 Moazenazdeh et al concluded that opium addiction was more frequent in those with CSFP than with CNF.19 It was also demonstrated that opium addiction, DM, and HTN are the main independent predictors of CSFP. Esmaeili Nadimi et al showed opium addiction could be considered a risk factor for microvascular coronary dysfunction, a term used instead of CSFP.20 Both studies included males and females but the present study investigated only males. Regardless of gender differences, some methodological differences and inherent confounders usually observed in consequences of opium use including cardiovascular
problems may have contributed to different study results.  
In the present study, the prevalence of opium use in those with CSFP was estimated as 18.2% that was lower than the rate reported by Moazenzadeh et al (43.5% in CSF group and 29.0% overall).  
The prevalence of substance abuse is different among various regions of Iran. In 2013, the Iranian National Network Scale Up survey was designed to estimate the prevalence of opium consumption and accordingly stratify the country into low, intermediate, and high-risk zones. Kerman and Qazvin were classified as high and low risk regions, respectively.  
In fact, the southeast of Iran is well known for high prevalence of opium consumption. The self-reported life time prevalence of opium use in Iran (12.9%, 95% CI: 6.8-19.0) is higher than the current consumption rate estimated as 5.4%. Lifetime prevalence of opium use is significantly higher in men than women (21.5% versus 4.0%).  
Finally, the current study demonstrated that male gender and history of chest pain are associated with CSFP, whereas, there are no significant differences between the two groups with and without this phenomenon in terms of HTN, HLP, and cigarette smoking.  

Study limitations  
The limitations of this study are similar to those of any other study that attempts to measure the effects of opium use on health or disease risk factors. Obtaining validated data from opium users is difficult as using opium is still formally forbidden in Iran. Opium is a mixture of different substances, about 70-80 substances mostly alkaloids, with different effects. Furthermore, drug impurity caused by various adulterants differs in various sources in different time periods and may lead to different results. Besides, large-scale clinical studies are warranted to better characterize this phenomenon, and most importantly, explore its potential relationship with opium consumption. Considering that opium dependent patients with CSFP have a history of chest pain, one may ask whether opium use was primary or secondary to the chest pain. It should be noted that this was a cross-sectional study in which the precedence or recency of opium use could not be assessed. Meanwhile, this study aimed to investigate the association between primary CSFP and opium use rather than the causal relationship.
Conclusion
This study indicated that opium use is not correlated with high primary CSFP. The study of the impact of opium use on cardiac function has inherent limitations that may render different results in different regions.

Acknowledgments
The authors would like to thank the technical assistance of the staff of the catheterization laboratory at Bu Ali Hospital. This research was conducted with administrative support from Qazvin University of Medical Sciences, Iran.

Author Contributions
HRJ, AA, and SMM designed the research study. ES collected data. AA and SMM Mirakbari analyzed the data. SMM wrote the paper.

Conflict of Interests
This study received no financial support or grant such as funds, fees, or holding stocks and shares in an organization that may profit or lose through publication of this paper. The authors have no conflict of interest to declare.

Ethical Approval
The ethics committee of Qazvin University of Medical Sciences approved the study with the code IR.QUMS.REC.1396.13.

Conflict of Interests
No conflict of interest to declare.

Ethical Approval
The ethics committee of Qazvin University of Medical Sciences approved the study with the code IR.QUMS.REC.1396.13.

References
1. Duarte DF. [Opium and opioids: a brief history.]. Rev Bras Anestesiol. 2005;55(1):135-46.
2. Mohabadi E, Baghdadost AA, Noroozi A, Molavi Vardanjani H, Hajei A, Nikbakht R, et al. Awareness and attitude towards opioid and stimulant use and lifetime prevalence of the drugs; a study in 5 large cities of Iran. Int J Health Policy Manag. 2019;8(4):222-32. doi: 10.15171/ijhpm.2018.128.
3. Javadi HR, Mirakbari SM, Allami A, Yazdi Z, Katebi K. Opioid-associated QT interval prolongation: a cross-sectional comparative study. Indian J Crit Care Med. 2021;25(1):43-7. doi: 10.1005/i-jcc.2020.03.004.
4. Zarghami M. Iranian common attitude toward opium consumption. Iran J Psychiatry Behav Sci. 2015;9(2):e2074. doi: 10.17795/jpbs2074.
5. Gholamhosseini A, Shoahouzhi B, Shokoohi M, Najafipour H. B12 and folate concentrations in opium addicts compared to healthy subjects: a case control study from Kerman coronary artery disease risk study. Addict Health. 2018;10(3):198-204. doi: 10.22122/ahj.2018.547.
6. Fattahi S, Khoshdeli F, Qavavati N, Droudy M. Strategic Problem of Development in Qazvin Province. 2016 Nov.; Available from: http://www.css.ir/Media/PDF/139605/14/63706057268742515.pdf. [Persian].
7. Sadr SS, Mahmoudinia SAR, Bakhthiar M. Frequency of opium use among diabetic patients and their attitude. Iran J Psychiatry Behav Sci. 2009;3(2):33-8.
8. Khadem H, Malekzaddeh R, Pourshams A, Jafari E, Salahi R, Semnani S, et al. Opium use and mortality in Golestan Cohort Study: prospective cohort study of 50,000 adults in Iran. BMJ. 2012;344:e2502. doi: 10.1136/bmj.e2502.
9. Rahimi N, Gnazshiti MH, Najafipour H, Shokoohi M, Marefati H. Potential effect of opium consumption on controlling diabetes and some cardiovascular risk factors in diabetic patients. Addict Health. 2014;6(1):1-6.
10. Alvarez C, Siu H. Coronary slow-flow phenomenon as an underrecognized and treatable source of chest pain: case series and literature review. J Investig Med High Impact Case Rep. 2018;6:2324709618789194. doi: 10.1177/2324709618789194.
11. Wang X, Nie SP. The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2011;11(1):37-43. doi: 10.3978/j.issn.2223-3652.2011.10.01.
12. Hasandoft K, Salari A, Soltanipour S, Dadkhah-Tirani H, Shad B, Rajabi E. Does opium have benefit for coronary artery disease? A systematic review. Res Cardiovasc Med. 2018;7(2):51-8. doi: 10.4103/rcm.rcm_12_17.
13. Javadi HR, Allami A, Mohammadi N, Alauddin R. Opium dependency and in-hospital outcome of acute myocardial infarction. Med J Islam Repub Iran. 2014;28:122.
14. Zhu X, Shen H, Gao F, Wu S, Ma Q, Jia S, et al. Clinical profile and outcome in patients with coronary slow flow phenomenon. Cardiol Res Pract. 2019;2019:9168153. doi: 10.1155/2019/9168153.
15. Mukhopadhyay S, Kumar M, Yusuf J, Gupta VK, Tyagi S. Risk factors and angiographic profile of coronary slow flow (CSF) phenomenon in North Indian population: an observational study. Indian Heart J. 2018;70(3):405-9. doi: 10.1016/j.ihj.2017.09.001.
16. Mullasari A, Victor SM. Coronary Slow Flow Phenomenon. The E-journal of European Society of Cardiology Council for Cardiology Practice [Internet]. 2013;11(25). Available from: https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/VOLUME-11/Coronary-slow-flow-phenomenon.
17. Mullasari A, Victor SM. Coronary slow flow phenomenon. EJ Eur Soc Cardiol Council Cardiol Pract. 2013;11(25).
18. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon: a new coronary microvascular disorder. Cardioology. 2002;97(4):197-202. doi: 10.1159/000063121.
19. Xia S, Deng SB, Wang Y, Xiao J, Du JL, Zhang Y, et al. Clinical analysis of the risk factors of slow coronary flow. Heart Vessels. 2011;26(5):480-6. doi: 10.1007/s00380-010-0081-5.
20. Moazzenzadeh M, Sarvar Azimzadeh B, Zare J, Shokouhi M, Sheikhwatian M. Clinical features and main determinants of coronary slow flow phenomenon in Iranian patients. Eur J Cardiovasc Med. 2010;1(2):57-60. doi: 10.5083/ejcm.2010.025.
21. Esmaeili Nadimi A, Pour Amiri F, Sheikh Fathollahi M, Hassanshahi G, Ahmadi Z, Sayadi AR. Opium addiction as an independent risk factor for coronary microvascular dysfunction: a case-control study of 250 consecutive patients with slow-flow angina. Int J Cardiol. 2016;219:301-7. doi: 10.1007/s00380-010-0081-5.
22. Najafi M. Opium and the heart: common challenges in investigation. I Tehran Heart Cent. 2010;5(3):113-5.
23. Ziaaddini H, Ziaaddini MR. The household survey of drug abuse in Kerman, Iran. J Appl Sci. 2005;5(2):380-2. doi: 10.3923/jas.2005.380.382.
24. Menati W, Valizadeh R, Menati R, Nazii M, Nazarzadeh M, Bidel Z. Determination of opium abuse prevalence in Iranian young people: a systematic review and meta-analysis. J Subst Use. 2017;22(1):3-10. doi: 10.3109/14659891.2015.1130181.
25. Caglar IM, Ozce B, Biyik I, Caglar FN, Akturk IF, Ugurlucan M, et al. Association between soluble lectin-like oxidized low-density lipoprotein receptor 1 levels and coronary slow flow phenomenon. Arch Med Sci. 2016;12(1):31-7. doi: 10.5114/ams.2015.51412.
26. Fallahzadeh MA, Salehi A, Naghshvarian M, Fallahzadeh MH, Poustchi H, Sepanlou SG, et al. Epidemiologic study of opium use in Pars Cohort Study; a study of 9000 adults in a rural southern area of Iran. Arch Iran Med. 2017;20(4):205-10.